About this page
Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.
How to read it
- Form 4
- The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
- Buy (P) and Sell (S)
- Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
- Value
- Shares times price, as reported on the filing.
- 10b5-1
- A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
- Late filing
- A Form 4 filed more than two business days after the trade.
- Vs. S&P 500
- How the stock did after the trade minus how the overall market did in the same weeks.
A real example
In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.
Explain it like I'm 13
If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.
Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.
ALUMIS INC. (ALMS): Insider Trades and Fund Holdings
In the past 12 months, ALUMIS INC. insiders reported 2 open-market purchases worth $10.7M and 8 sales worth $1.55M; 0 of the sales were reported as made under a 10b5-1 trading plan.
Timeline: news and trades
Company filings (8-K), insider trades, notices of planned sales (Form 144), Congress trades and fund moves in the past year, newest first.
- Sep 8, 2026Insider buyDirector Srinivas Akkaraju bought $5.8 million
- Sep 8, 2026Insider saleDirector Srinivas Akkaraju sold $1 million
- Sep 4, 2026Insider buyDirector Srinivas Akkaraju bought $4.9 million
- Aug 13, 2026NewsCompany reported: Quarterly or annual results
- Aug 3, 2026Insider saleCFO John R. Schroer sold $86,546
- Aug 3, 2026Insider saleChief Business & Strategy Ofcr Roy C. Hardiman sold $70,988
- Aug 3, 2026Insider saleChief Scientific Officer David M. Goldstein sold $68,457
- Aug 3, 2026Insider saleChief Development Officer Mark Christopher Bradley sold $67,824
- Aug 3, 2026Insider saleChief Medical Officer Jorn Drappa sold $64,527
- Aug 3, 2026Insider saleGeneral Counsel Sanam Pangali sold $35,969
- Jul 6, 2026Insider saleGeneral Counsel Sanam Pangali sold $140,000
- Jun 30, 2026FundRenaissance Technologies cut 69% in Q2 2026 (13F filed Aug 13, 2026)
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Sep 9, 2026.
| Filed | Insider | Type | Value | Score |
|---|---|---|---|---|
| Sep 9 | Srinivas AkkarajuDirector | ▲ BUY | $5.81M | 57 |
| Sep 9 | Srinivas AkkarajuDirector | ▲ BUY | $4.92M | 54 |
| Sep 9 | Srinivas AkkarajuDirector | ▼ SELL | $1.01M | |
| Aug 5 | John R. SchroerCFO | ▼ SELL | $87K | |
| Aug 5 | Roy C. HardimanChief Business & Strategy Ofcr | ▼ SELL | $71K | |
| Aug 5 | David M. GoldsteinChief Scientific Officer | ▼ SELL | $68K | |
| Aug 5 | Mark Christopher BradleyChief Development Officer | ▼ SELL | $68K | |
| Aug 5 | Jorn DrappaChief Medical Officer | ▼ SELL | $65K | |
| Aug 5 | Sanam PangaliGeneral Counsel | ▼ SELL | $36K | |
| Jul 8 | Sanam PangaliGeneral Counsel | ▼ SELL | $140K |
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Srinivas Akkaraju | Director | 2 | $10.7M | 1 | $1.01M |
| John R. Schroer | CFO | 0 | $0 | 1 | $87K |
| Roy C. Hardiman | Chief Business & Strategy Ofcr | 0 | $0 | 1 | $71K |
| David M. Goldstein | Chief Scientific Officer | 0 | $0 | 1 | $68K |
| Mark Christopher Bradley | Chief Development Officer | 0 | $0 | 1 | $68K |
| Jorn Drappa | Chief Medical Officer | 0 | $0 | 1 | $65K |
| Sanam Pangali | General Counsel | 0 | $0 | 2 | $176K |
Buybacks and executive pay
ALUMIS INC. spent $17,000 buying back its own shares in 2025.
From the company's XBRL data filed with the SEC. "Actually paid" is the SEC's pay-versus-performance measure, which counts changes in the value of stock awards. "Value of $100 invested" is the company's cumulative shareholder return as reported, usually measured from five years earlier. See all buybacks and CEO pay across companies.
57 Srinivas Akkaraju (Director), 2026-09-08. What the score means
A All 10 insider trades reported on time. How it is graded
Tracked funds that report ALMS
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 23,335 | $657K | ▼ −69.0% |
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →